EUR 40 million Hematology Project Aims for Faster, Better Care for Patients with Blood Diseases

THE HAGUE, The Netherlands, January 9, 2017 /PRNewswire/ --

Patients struggling with blood disorders may look forward to more rapid and efficient treatment from the outcomes of the HARMONY project, an initiative that aims to create a roadmap for better access and care for patients with various blood diseases with the use of big data.
(Logo: )

(Logo: )

(Logo: )

(Logo: )

Made up of 51 partners from 11 European countries, including 7 pharmaceutical companies, HARMONY will put together anonymous patient data to unlock valuable knowledge on multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), myelodysplastic syndromes (MDS) and blood disorders in infants and children.
HARMONY will build on pre-existing, long-lasting collaborations between academics, clinicians, patient organizations and the pharmaceutical industry. It shall further advance management of these diseases through a more efficient process of treatment development and rapid decision-making. The expected outcome will be better prognosis and quicker improved treatment decisions.
The project brings together key players in the clinical, academic, patient, HTA (health technology assessment), regulatory, economical, ethical and pharmaceutical fields to:

- Developing a data sharing platform that empowers clinicians and policy
stakeholders to improve decision-making
- Establishing a network reflecting the European HMs landscape
- Defining clinical endpoints and standard outcomes in ALL (paediatric & adult), NHL, MM,
- Alignment of key stakeholders on relevance of these outcomes (policy makers, payers,
- Providing means for analysing complex data sets comprising different layers of
- Identifying specific markers for early registration of innovative and effective
therapies for HMs

The HARMONY project's final deliverable is a big data platform that will integrate disease information in order to better understand the diseases and how to treat most efficiently. HARMONY will achieve this from a pan-European perspective by uniting and aligning European stakeholders and key opinion leaders in the field. The 5-year project will start in January 2017 and is funded through the Innovative Medicines Initiative (IMI) ; Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
It should be made clear in the text and layout that the communication reflects the author's view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.
Follow us on: Facebook [ ] | LinkedIn [ ] | Twitter [ ]  
Partners in HARMONY 

Project management 
Instituto de Investigacion Biomedica de Salamanca (IBSAL), Spain 
Instituto de Investigacion Sanitaria del Hospital La Fe de Valencia (HULAFE), Spain 
Celgene International II SARL, Switzerland 
Novartis, Switzerland 
Synapse Research Management Partners, S.L. (SYNAPSE), Spain 


Universitaet Ulm (UULM), Germany* 
Alma Mater Studiorum - Universita di Bologna (UNIBO), Italy* 
European Hematology Association (EHA), The Netherlands* 
ELN Foundation (ELN), Germany* 
GMV Soluciones Globales Internet S.A.U. (GMV), Spain* 
European Alliance for Personalised Medicine (EAPM), Belgium 
Medizinische Universitaet - Wien (MUW), Austria* 
Erasmus Universiteit Medisch Centrum Rotterdam (EMC), The Netherlands 
University of Navarra (UNAV), Spain 
Universita degli Studi di Torino (UNITO), Italy 
Stichting VUmc, The Netherlands 
The Chancellor, Masters and Scholars of the University of Cambridge (UCAM), United
University of Rome 'Tor Vergata' (URTV), Italy 
Goethe University Frankfurt (GUF), Germany 
Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL), France 
Jose Carreras Leukaemia Research Institute (IJC), Spain 
European Research Initiative on CLL e.v. (ERIC), Germany 
Masaryk University (MU), Czech Republic 
Fundacio privada Institut D'investigacio Oncologica de Vall-Hebron (VHIO), Spain 
The Lymphoma Scientific Association (LYSA), France 
Ludwig-Maximilians-Universitaet - Muenchen (LMU-Muenchen), Germany 
Barts Health NHS Trust (BHT), United Kingdom 
Groupe Francophone des Myelodysplasies (GFM), France 
Heinrich-Heine-Universitaet - Duesseldorf (UDUS), Germany 
Fondazione Italiana per lo studio delle sindromi mielodisplastiche onlus (FISMonlus),
University of Newcastle upon Tyne (UNEW), United Kingdom 
German Society of Pediatric Oncology-Hematology GmbH gemeinnuetzig (GPOH), Germany 
Ospedale Pediatrico Bambino Gesu (OPBG), Italy 
University of York (UoY), United Kingdom 
European Organisation for Research and Treatment of Cancer (EORTC), Belgium 
European Society for Blood and Marrow Transplantation (EBMT), The Netherlands 
Flanders Institute of Biotechnology (VIB), Belgium 
University of Helsinki (UH), Finland 
Assistance Publique - Hopitaux de Paris (AP-HP), France 
Genome Research Limited (GRL-SANGER), United Kingdom 
MediSapiens Ltd (MS), Finland 
MLL Munich Leukemia Laboratory GmbH (MLL), Germany 
LeukaNET (LeNET), Germany* 
National Institute for Health and Care Excellence (NICE), United Kingdom 
Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS), Spain 
Bundesinstitut fuer Arzneimittel und Medizinprodukte (BfArM), Germany 
Amgen, United Kingdom* 
Janssen Pharmaceutica NV, Belgium* 
Bayer Aktiengesellschaft, Germany* 
Menarini Ricerche S.p.A., Italy* 
Takeda, United Kingdom* 

*Work package leaders and co-leaders 


European Hematology Association

CONTACT: Contact information:, +31 (0)6 2011 1055

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234